GlaxoSmithKline has appointed Emma Walmsley as its new chief executive.
Walmsley will replace Andrew Witty who had previously announced his decision to retire on March 31, 2017.
Her appointment is likely to be seen as a signal that GSK will retain the consumer business as a core part of its operations.